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Pulmonary arterial hypertension (PAH) is a devastating disease of the small
pulmonary arteries and arterioles, characterized by intimal fibrosis, medial hypertrophy and
plexiform lesions. When untreated both the idiopathic form (IPAH, formerly termed primary
pulmonary hypertension, PPH) and PAH related to various other conditions such as
scleroderma (SSc) often take a progressive course with high mortality. There is ongoing
search for disease-specific treatments that are able to improve survival in these patients. The








) antagonist bosentan has been shown to improve exercise




To determine the long-term effects of bosentan on survival, patients
from the two double-blind, randomized trials and their open-label extensions, treated with
first-line bosentan, were followed for up to 3 years. Data on survival were collected between
September 1999 (first patient included in the placebo-controlled trials) and December 2002.
Vital status was verified in each patient. The survival cohorts of these patients were compared
with either the predicted survival for each patient based on an equation from the National




Observed survival up to 36 months was reported as a Kaplan-Meier estimate in
three cohorts: (1) In 169 PPH patients treated with first-line bosentan, 1- and 2-year survival
was 96% and 89%, respectively, vs. predicted untreated survival at 1 and 2 years of 69%
and 57%, respectively; (2) in 50 patients with PAH associated with SSc (PAH-SSc), 1-, 2- and













respectively, from registry data of untreated PAH-SSc patients; and (3) in 139 PPH patients
in WHO functional class III, 1- and 2-year survival was 97% and 91%, respectively, vs. 91%





The present analyses suggest that first-line bosentan therapy, followed by the
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Pulmonary arterial hypertension (PAH) is defined as a
group of diseases characterized by a progressive increase of
pulmonary vascular resistance, which is debilitating and
ultimately leads to right ventricular failure and premature
death [1]. Usually PAH has a poor outcome, but the natural
history of the disease is heterogeneous, with some patients
dying within months of diagnosis and others living for dec-
ades [2]. The underlying diagnosis is associated with the
prognosis: for example, patients with PAH related to con-
genital heart disease have a substantially higher life expectancy
than patients with the idiopathic form (IPAH, formerly
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termed primary, PPH) or with PAH related to connective
tissue disease (Table 1).
According to a recent review published as part of the
ACCP evidence-based clinical practice guidelines for PAH,
apart from the underlying disease, certain parameters,
assessed at baseline, predict a worse prognosis. Parameters
with high-quality evidence include advanced World Health
Organisation (WHO) functional class (FC), low 6-min walk
distance and presence of pericardial effusion, while for
haemodynamic, electrocardiographic and laboratory find-
ings the existing evidence is fair or even low and the net
predictive value consequently limited [2].
 
Need for long-term observations to assess prognosis
 
While there is no cure for PAH, medical treatment has made
great progress over the past decade. Usually, placebo-
controlled clinical studies are limited to short observation
periods of approximately 3–4 months, which is regarded to
be appropriate for registration purposes by the relevant
authorities. However, the results of short-term treated cannot
be generally extrapolated to long-term use, as exemplified
by the results of a trial with beraprost, an oral prostacyclin
analogue. In a 12-month double-blind, randomized, placebo-
controlled study of 116 patients with WHO functional class
II or III PAH related to either connective tissue diseases or
congenital systemic to pulmonary shunts, beraprost increased
time to disease progression at 6 months, and improved exer-
cise endurance compared with placebo at 3 and 6 months
[3]. These effects dissipated at 9 and 12 months of therapy
and were not associated with a detectable benefit in symp-
tomatic status or quality of life as measured by standardized
instruments, nor with haemodynamic improvement. In
addition, disappointing results on long-term inhaled iloprost
treatment have recently been reported [4].
These examples show that long-term observations are
necessary to determine the impact of treatment on prognosis
of the patients.
However, in view of the rapid progression of PAH in many
cases, long-term placebo-controlled therapy is ethically not
acceptable; treatment must not be delayed in these patients
[5]. Larger head-to-head studies of drugs are not available,
and there is a trend in PAH therapy to combine treatments
early or as an add-on strategy [6].
 
Endothelin antagonism in PAH
 
Three different pathways are known to be involved in the
pathophysiology in PAH (prostacyclin, nitric oxide, and
endothelin (ET) pathways). Substantial evidence shows that
ET plays a key role. The effects of ET include proliferation,
vascular hypertrophy, inflammation, fibrosis and vaso-
constriction [7]. ET levels correlate with PAH disease severity









) mediate these deleterious effects and preclinical
data have demonstrated that dual blockade is superior com-




 blockade in terms of haemodynamic













 receptor antagonist bosentan in the treat-
ment of PAH patients in WHO (World Health Organisation)
functional class III or IV (III in the European Union) [10,11].
In the pilot 12-week trial (study 351), treatment with bosentan
at a dose of 62·5 mg twice daily for 4 weeks, and at 125 mg
twice daily thereafter, improved the primary endpoint exercise
capacity measured by the 6-min walk test (mean placebo-




 = 0·02). In
addition, improvements in pulmonary vascular resistance
were observed, and patients also experienced a reduced
Borg dyspnea index and an improved functional capacity.
These preliminary results were confirmed by the pivotal
16-week Bosentan Randomized Trial of Endothelin Antag-
onist Therapy (BREATHE)-1 [11], in which 213 PAH
patients in functional class III or IV (IPAH, PAH-SSc, PAH
associated with systemic lupus erythematosus) were ran-
domly assigned to receive placebo or bosentan (at a dose
of 62·5 mg twice daily for 4 weeks; thereafter either 125 mg
or 250 mg twice daily for at least 12 weeks). The mean effect
of treatment on the 6-min walk test was a placebo-corrected





 0·001). Patients receiving bosentan also had improve-
ment in the time to clinical worsening (death, lung trans-
plantation, hospitalization for pulmonary hypertension, lack
of clinical improvement or worsening leading to discon-
tinuation of treatment, a need for epoprostenol therapy
or atrial septostomy). A substudy of 85 patients showed that
Table 1 Survival in PAH with various underlying diagnoses (natural history)
Diagnosis Year 1 Year 2 Year 3 Year 4 Year 5
CHD 0·92 (2) 0·885 (2) 0·77 (1) 0·77 (1)
Connective tissue disease 0·67 (3) 0·405 (2) 0·37 (2)
HIV 0·58 (1) 0·39 (2) 0·21 (1)
PPH 0·79 (21) 0·66 (12) 0·59 (14) 0·28 (3) 0·48 (14)
Portopulmonary hypertension 0·64 (1)
*Data (number of studies) are presented as unweighted and unadjusted averages of entire data set.
CHD, congenital heart disease; HIV, human immunodeficiency virus; PPH, primary pulmonary hypertension.
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bosentan also improved haemodynamic parameters meas-
ured noninvasively by means of a transthoracic Doppler
echocardiography [12].
 
Bosentan pilot study: 1-year results
 
Twenty-nine of the original 32 patients with PAH (IPAH or
associated with SSc) who participated in the pilot 12-week
study participated in an open-label extension study [13]. All
patients received bosentan open-label (62·5 mg twice daily for
4 weeks and then 125 mg twice daily). At month 6, assessed
patients continuing bosentan treatment maintained the
improvement in walk distance observed at the end of the




 11 m), and patients starting bosentan




 13 m. Long-
term treatment with bosentan for > 1 year was associated with
an improvement in haemodynamic parameters and modified
WHO functional class. The long-term results confirmed sus-
tained benefits on exercise capacity and haemodynamics [13].
 
Survival analysis 1: first-line bosentan in IPAH 
patients vs. historical controls
 
Recently, we published the survival analysis of idiopathic
PAH patients, who were from both the bosentan randomized
trials and the open-label extensions treated with first-line
bosentan [14]. Of the 245 patients enrolled in the placebo-
controlled studies, PAH was considered primary in 177, and
analyses were performed in 169 of these patients with PPH
(IPAH) who received bosentan as first-line therapy for their
disease, either during the placebo-controlled study or its
extension. Eight patients initially randomized to placebo,
seven of whom were withdrawn and treated with alternative
therapies and one who died before the end of the placebo-
controlled trial, did not receive bosentan as first-line therapy
and were excluded from the analysis. Decisions on other
treatments were taken according to the discretion of the
treating physician. During the placebo-controlled studies,
patients requiring prostanoid therapy were withdrawn from the
study; during the extension studies, prostanoid or other
alternate oral therapies could be administered with continued
bosentan therapy. Data on vital status and alternative treat-
ments were collected from September 1999 (start of the first
placebo-controlled study) to 31 December 2002 (data cut-off),
whether or not the patients remained on study treatment
throughout. Table 2 shows the baseline characteristics of all
169 patients included in the analysis. Survival was assessed
from the start of bosentan treatment to death or data cut-off.
All bosentan-treated PPH patients were included in the
analyses (intent to treat); patients lost to follow up were con-
sidered dead at the last known contact, the most conservative
assumption. Changes in treatment did not affect the survival
analysis. The annual death rate was obtained by interpolation
of the observed data assuming an exponential distribution.




 0·5 years. The majority
of patients were on the recommended bosentan 125 mg
b.i.d. dose, 1% were on a quarter of this dose, 11·3% on
half this dose and 10·1% were on double this dose. Table 3
summarizes the outcomes of bosentan-treated patients.
Kaplan-Meier survival estimates were 96% at 1 year and
89% at 2 years (Fig. 1). The annual death rate of patients on
bosentan was 5·5%. Furthermore, 85% and 70% of patients,
respectively, remained alive and on bosentan monotherapy at
1 and 2 years (Fig. 2) [14]. The observed survival rates com-
pared favourably with predicted survival, which was determined
for each patient according to the National Institutes of Health
(NIH) Registry formula. This formula, published in 1987,
is based on the outcomes from 187 PPH patients in the NIH
registry and reflects the natural history of disease at a time when
no specific treatment was available [15]. It has been vali-
dated prospectively in a different cohort of 61 PPH patients
[16]. Using the equation in our dataset, the predicted 1- and
2-year survival rates were 69% and 57%, respectively, and
thus substantially lower than those observed on bosentan.
 
Survival analysis 2: first-line bosentan in PAH-SSc 
patients vs. registry data
 
A similar analysis to that of IPAH patients was carried out
on the patients with PAH-SSc who participated in the above
Table 2 Demographic and baseline characteristics of 169 
bosentan-treated patients with idiopathic pulmonary arterial 
hypertension
Subjects (n) 169
Sex male/female (%) 21/79
Age (years)
Mean ± SD 46 ± 16
Range 13–80
WHO functional class (%)
I/II 1/8*
III/IV 82/9
Time from diagnosis (months)†
Mean ± SD 32 ± 41
Range 0·3–326
Haemodynamics (mean ± SD)†
Cardiac index (L min−1 m−2) 2·35 ± 0·80
PVR (Wood units) 12·9 ± 8·4
mPAP (mmHg) 57·1 ± 16·0
mRAP (mmHg) 10·1 ± 5·9
Walk test (m)
Mean ± SD 345 ± 87
*All patients entered the pivotal studies in functional class III or 
IV, but 15 (9%) patients in the placebo group improved before 
being switched to bosentan in the extension study.
†Time from diagnosis and haemodynamic data were available for 
157–169 bosentan-treated patients; for most of these patients, data 
were available only at the start of the placebo-controlled study.
Patients from the bosentan pivotal studies and their open-label 
extensions.
From McLaughlin et al. with permission [14].
PPH, primary pulmonary hypertension (= idiopathic PAH); 
WHO, World Health Organization; PVR, pulmonary vascular 
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placebo-controlled bosentan studies. The 50 patients in the
long term dataset were predominantly female (84%), with




 10·5 years. Four per cent, 90% and
6% of patients were in WHO functional class II, III, and










 0·8 years. Eight patients (16%) received epoprostenol
as add-on therapy and seven patients (14%) received it after
discontinuation of bosentan. Survival was 82% after 1 year,
67% after 2 years and 64% after 3 years [17]. These data were

















28% at 1, 2 and 3 years, respectively [18]. According to the
authors’ conclusion, long-term treatment may stabilize the
disease and appears to have a favourable effect on long-term
outcomes in comparison with registry data [16].
 
Survival analysis 3: first-line bosentan in IPAH class 
III patients vs. a retrospective cohort on first-line 
epoprostenol
 
The survival data of the two prospective, double-blind,
placebo-controlled bosentan studies and their open-label
extensions were also compared with a cohort of patients that
received epoprostenol as initial treatment [19]. The data on
epoprostenol were taken from patient records in five major
referral centres which also participated in the bosentan
trials. To ensure comparability of regimens, the analysis was
restricted to 139 bosentan and 346 epoprostenol IPAH
patients in WHO functional class III. While demographics
were similar in both cohorts, patients in the epoprostenol
cohort had more severe disease (lower 6-min walk test













). Kaplan-Meier survival estimates in the
bosentan cohort at 1 and 2 years were 97% and 91%,
respectively, and in the epoprostenol cohort were 91% and




-value = 0·022). Cox regres-
sion to adjust for differences in baseline factors showed
a greater probability of death in the epoprostenol cohort




 = 0·006 independent step-wise
model, 1·7–2·7 alternate analyses). In all Cox regression
models used, the probability of death was never higher in
the bosentan cohort compared with the epoprostenol
cohort, regardless of the factors imputed for adjustment. In
a matched-pair analysis of cohorts of 83 patients in each,
survival estimates of bosentan and epoprostenol were nearly
identical (Fig. 3). In the bosentan cohort, 87% and 75% of





In all current, randomized, placebo-controlled trials inves-
tigating disease-specific therapy for PAH, such as bosentan,
Table 3 Outcomes in bosentan-treated patients with idiopathic 
pulmonary arterial hypertension (IPAH)*
Subjects (n) 169
Duration of observation for survival (years)
Mean ± SD 2·1 ± 0·5
Range 0·1–3·3
Patients lost to follow up (n) 1
Lung transplantations (n) 3
Deaths n (%) 20 (13)†
Transfers to/additions of prostanoids or 
alternative oral PPH therapies n (%)
39 (24)‡
Patients who received alternative 
treatment in addition to bosentan (n)
19
Discontinuations of bosentan without 
other event or treatment (n)
4
*According to the classification applicable during the initiation 
of the pivotal studies, these were patients with primary pulmonary 
hypertension (PPH) patients.
†Includes the one patient lost to follow up; ‡includes the one 
patient lost to follow up and three patients with a period of 
unknown treatment.
From McLaughlin et al. with permission [14].
Figure 1 Survival in first-line bosentan therapy vs. predicted 
survival using National Institutes of Health (NIH) Registry formula 
for pulmonary arterial hypertension (PAH). Dashed line: observed 
survival; solid line: predicted survival. Adapted with permission 
from McLaughlin et al. 2005 [14].
Figure 2 Vital status and treatment at 12 and 24 months of follow 
up in the bosentan cohort. All 169 patients were followed for 
12 months; 132 patients were followed for at least 24 months. 
Percentages are based on the number of patients followed. Adapted 
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epoprostenol, beraprost, treprostinil, sildenafil and others,
treatment duration was short and exercise-related endpoints
were chosen as the primary end point, usually the 6-min
walk test [5]. Immediate relief by symptomatic improve-
ments is important for the patient; however, other treatment
goals are equally or more important. The patient’s perspec-
tive is reflected by measurements of quality of life, which
has been increasingly addressed in clinical studies, including
those regarding bosentan [20]. But these are first steps, and
augmenting survival is the paramount goal [21].
In patients with a significant acute response to a short-
acting vasodilator, calcium-channel blocker (CCB) treat-
ment, usually in IPAH patients in WHO functional class II
or III, has been shown to increase survival compared with
historical data in a limited number of adults or children,
respectively [22–24]. However, only approximately 10–20%
of adults respond and an even lower proportion gain a
sustained benefit from CCB therapy [22,25].
Chronic intravenous epoprostenol (synthetic prostacyc-
lin) has previously been shown to improve prognosis: in a
series of uncontrolled studies in WHO functional class III
or IV, survival was improved compared with historical con-
trols [24,26–28]. Furthermore, a randomized, controlled
trial showing improved survival has also been published but
is limited to severe cases followed up over 12 weeks [29].
In the two recent cohort analyses of IPAH patients, the one
conducted at our institution revealed an observed survival
with epoprostenol at 1, 2, 3 and 5 years of 88%, 76%, 63%
and 47%, respectively [26]. In the other series, at Béclère/
Clamart, the corresponding rates were 85%, 70%, 63% and
55%, respectively [27]. Currently, epoprostenol is recom-
mended as first-line for patients with WHO class III and IV
[1,30]. However, the drug is costly, inconvenient and
associated with major morbidity, especially owing to catheter-
based infections. The inhaled prostacyclin alternative
iloprost, which has a longer half-life and is less expensive
than epoprostenol, has shown improvement in symptoms
and haemodynamics in IPAH for up to 2 years [31], but in
a recent 5-year study only a minority of patients could be
stabilized on first-line iloprost monotherapy [4]. The oral
prostacyclin beraprost did not improve survival [3].
Against the background of the considerable limitations of
existing therapies, it is of major importance that the ET
receptor antagonist bosentan shows a favourable effect on
survival that seems at least comparable to that of epopros-
tenol in WHO class III IPAH patients. As ethical and
practical considerations prevent placebo-controlled long-
term trials, the predicted survival is calculated based on a
regression equation. This equation was developed in the
1980s from the large NIH registry of PPH patients to
predict the survival chances of patients on the basis of
haemodynamic variables [15]. It has been validated in an
independent series of patients [16] and still represents the
best available tool for long-term survival analysis [32]. Thus,
it was used in subsequent indirect comparisons with
patients treated with various PAH drugs as well as in the
bosentan dataset described earlier [4,14,26–28]. The
predictive value of the NIH formula, however, may be
compromised by an improvement of standards of care for
PAH therapy (e.g. earlier diagnosis, improved background
therapy such as widespread use of anticoagulation). Other
issues to be considered in the interpretation of the data are
the limited number of bosentan patients that have been
followed for 3 years and the low number of patients in WHO
functional class IV. There were various add-on or switch
therapy strategies that were possible in addition to bosentan
monotherapy, which may have contributed to the overall
treatment effect [32]. Nevertheless, this reflects the current,
practical approach to the medical therapy of PAH.
Survival in bosentan-treated patients was lower in SSc
patients than in IPAH patients, which confirms earlier data










 [33] Although the results in the small dataset
on bosentan did not reach significance, they indicated both
improvements in exercise capacity as well as enhanced
prognosis. In conclusion, the present analyses suggest that
first-line bosentan therapy, followed by the addition of other
disease-specific therapies as required, improves survival in




The studies and analyses described in this paper were carried









 Guidelines on diagnosis and treatment of 
pulmonary arterial hypertension. The Task Force on Diagnosis 
and Treatment of Pulmonary Arterial Hypertension of the 









Figure 3 Kaplan-Meier survival curves for matched cohorts of 
functional class III patients with idiopathic pulmonary arterial 
hypertension (PAH) treated with bosentan or epoprostenol. 
Kaplan-Meier survival curves for class III idiopathic PAH patients 
treated with bosentan (solid line) or epoprostenol (dashed line) – 
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